The BPR* is happening and will affect all companies making disinfectants that are sold in Europe.
How Lonza can help you survive the
are able to offer you a number of different approaches:
you with information, analytical methods and advice for our broad portfolio of
actives that may be used in your formulations.
opportunity to produce and/or market a range of established and new
disinfectant formulations that we intend to support through the product
authorization process of the BPR* for specified EU Member States. These
formulations could easily and cost-effectively be added into your product range
and marketed under your own trade name using Lonza’s previously generated
efficacy data. The cost of a data package and authorisation fees could easily
exceed €250,000 per product.
the following steps starting today…
sure your product is on the market, in each of your target countries, before
the date of inclusion of the active substance, to allow continuity of supply.
This date may be earlier depending on the transitional arrangements in each
member state. Failure to have a product on the market by the date of inclusion
of the active substance could mean the loss of over 3 years of business
with Lonza to assess your current and future product needs
with Lonza during the BPR to ensure no interruption to business
options to purchase and/or manufacture (following our original formulation
recipe) our supported disinfectant products
is committed to investing in innovative solutions that meet our customers’
current and future needs. New and improved disinfectant products are in
Contact Lonza for further details regarding the
decision on inclusion for DDAC and Lonzabac® 12 for PT2 and PT4.
* Biocidal Product Directive; directive 98/8/EC
** Biocidal Product Regulation;
regulation (EU) 528/2012